CompletedPhase 1

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

UCLA Hematology/Oncology

Los Angeles, California, United States

+11 additional locations

Save this trial

UCLA Hematology/OncologyLos Angeles, California, United States
Sarah Cannon Research Institute at HealthONEDenver, Colorado, United States
Florida Cancer SpecialistsSarasota, Florida, United States
Winship Cancer Institute, Emory UniversityAtlanta, Georgia, United States
Northwestern Memorial HospitalChicago, Illinois, United States
Columbia University Irvine Medical CenterNew York, New York, United States
University of Cincinnati Medical CenterCincinnati, Ohio, United States
UPMC Hillman Cancer CenterPittsburgh, Pennsylvania, United States
Tennessee OncologyNashville, Tennessee, United States
The University of Texas MD Anderson Cancer CenterHouston, Texas, United States
Huntsman Cancer Institute, University of UtahSalt Lake City, Utah, United States
Froedtert Hospital & The Medical College of WisconsinMilwaukee, Wisconsin, United States